Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$740K Buy
5,758
+1,469
+34% +$172K 0.11% 96
2026
Q1
$516K Buy
4,289
+477
+13% +$55.1K 0.1% 103
2025
Q4
$401K Buy
3,812
+500
+15% +$46.9K 0.08% 115
2025
Q3
$278K Sell
3,312
-238
-7% -$19.6K 0.06% 140
2025
Q2
$281K Buy
3,550
+272
+8% +$21.6K 0.06% 137
2025
Q1
$294K Sell
3,278
-109
-3% -$10.2K 0.08% 123
2024
Q4
$337K Buy
3,387
+9
+0.3% +$928 0.1% 111
2024
Q3
$384K Sell
3,378
-62
-2% -$7.37K 0.11% 106
2024
Q2
$426K Sell
3,440
-24
-0.7% -$3.09K 0.14% 88
2024
Q1
$457K Buy
3,464
+416
+14% +$51.3K 0.16% 89
2023
Q4
$332K Sell
3,048
-292
-9% -$30.3K 0.13% 100
2023
Q3
$344K Buy
+3,340
New +$360K 0.15% 91
2023
Q2
Sell
-2,186
Closed -$233K 107
2023
Q1
$233K Buy
2,186
+103
+5% +$11.1K 0.25% 58
2022
Q4
$231K Buy
+2,083
New +$213K 0.28% 64

Other funds holding MRK

Verum Partners's MRK Position: Q2 2026 in Review

Verum Partners increased its Merck (MRK) stake by 34% in Q2 2026, buying an estimated $172K and bringing the position to 5,758 shares worth $740K. The position accounts for 0.11% of the portfolio, ranked #96.

Verum Partners first reported a position in MRK in Q4 2022 and has held it in 14 quarters since. 1,034 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Verum Partners held 5,758 shares of Merck worth $740K as of Q2 2026.
  • Verum Partners bought 1,469 Merck shares in Q2 2026, an estimated $172K.
  • Merck made up 0.11% of Verum Partners's portfolio in Q2 2026, its #96 holding.
  • Verum Partners first reported a position in Merck in Q4 2022 and has held it in 14 quarters since.
  • 1,034 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Verum Partners's 13F filing for Q2 2026, filed 22 Jul 2026.